| Date | Time | Source | Headline | Symbol | Company |
| 10/31/2023 | 4:03PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/23/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/16/2023 | 12:36PM | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/16/2023 | 8:09AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/12/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/06/2023 | 8:08AM | Edgar (US Regulatory) | Form ARS - Annual Report to Security Holders | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/06/2023 | 8:05AM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/06/2023 | 8:03AM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/03/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver | NASDAQ:GALT | Galectin Therapeutics Inc |
| 10/02/2023 | 7:43AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/27/2023 | 2:03PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/26/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/18/2023 | 9:53AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/11/2023 | 4:38PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/11/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/07/2023 | 12:00PM | GlobeNewswire Inc. | Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 | NASDAQ:GALT | Galectin Therapeutics Inc |
| 09/01/2023 | 7:16AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 08/15/2023 | 4:05PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 08/14/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 08/14/2023 | 7:55AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:GALT | Galectin Therapeutics Inc |
| 08/14/2023 | 7:51AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:GALT | Galectin Therapeutics Inc |
| 07/31/2023 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 07/20/2023 | 7:40AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 07/17/2023 | 8:02AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 07/03/2023 | 7:48AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GALT | Galectin Therapeutics Inc |
| 06/16/2023 | 7:51AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 06/01/2023 | 7:54AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 05/16/2023 | 7:48AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:GALT | Galectin Therapeutics Inc |
| 05/15/2023 | 8:00AM | GlobeNewswire Inc. | Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update | NASDAQ:GALT | Galectin Therapeutics Inc |
| 05/15/2023 | 7:56AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:GALT | Galectin Therapeutics Inc |